Compounds > ly 181984
Page last updated: 2024-12-08

ly 181984

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID160725
CHEMBL ID7829
SCHEMBL ID4612056
MeSH IDM0173696

Synonyms (23)

Synonym
OPREA1_496398
OPREA1_437589
MS-8358
1-(4-chlorophenyl)-3-(4-methylbenzenesulfonyl)urea
mpcu
STK021427
n-[(4-chlorophenyl)carbamoyl]-4-methylbenzenesulfonamide
CHEMBL7829
ly-181984
AKOS000646724
3955-50-8
1-(4-chlorophenyl)-3-(4-methylphenyl)sulfonylurea
benzenesulfonamide, n-(((4-chlorophenyl)amino)carbonyl)-4-methyl-
n-(4-methylphenylsulfonyl)-n'-(4-chlorophenyl)urea
ly 181984
1-(4-chlorophenyl)-3-((4-methylphenyl)sulfonyl)urea
YOIDHZBOHMNTNP-UHFFFAOYSA-N
n-[[(4-chlorophenyl)amino]carbonyl]-4-methylbenzenesulfonamide
SCHEMBL4612056
HMS3429J05
DTXSID30192669
mfcd00416316
ly181984

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In general, several analogs demonstrated excellent growth inhibitory activity in the 6C3HED model when dosed orally or intraperitoneally."( Sulfonimidamide analogs of oncolytic sulfonylureas.
Bewley, JR; Boder, GB; Ehlhardt, WJ; Gates, SB; Grindey, GB; Klingerman, KK; Ray, JE; Rinzel, SM; Schultz, RM; Toth, JE; Weir, LC; Worzalla, JF, 1997)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID38318Antitumor activity in vivo and the activity was determined as percent increase in life span determined against B-16-melanoma (ascites) cell lines1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID43708In vitro cytotoxicity against CCRF-CEM cells1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID44601Antitumor activity in vivo expressed as percent of inhibition in C-26-colon carcinoma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID7270Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID123899Antitumor activity against Murine K1735/M2 Melanoma xenograft expressed as body weight change from day 0 to 20 in mice at dose of 300 mg/kg oral administration1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
AID103635Antitumor activity in vivo expressed as percent of inhibition in Lewis-lung carcinoma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID25331Affinity constant was determined along with the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID105469Cytotoxic Activity against human tumor MOLT-4 cell line with 20 micro g/mL1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
AID86393Cytotoxic activity against human tumor HepG2 cell line1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
AID153378Antitumor activity in vivo and the activity was determined as percent increase in life span determined against P388-lymphocytic leukemia tumor cell lines1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID99342Antitumor activity in vivo and the activity was determined as percent increase in life span determined against L1210V-lymphocytic leukemia tumor cell lines1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID219579Antitumor activity in vivo expressed as percent of inhibition in X5563-plasma cell myeloma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID220263Antitumor activity in vivo expressed as percent of inhibition in Yoshida-sarcoma (rat) cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID152330Antitumor activity in vivo expressed as percent of inhibition in P1534J-lymphatic leukemia cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID117211In vivo antitumor activity against subaxillary implanted 6C3HED lymphosarcoma implanted in C3H mice at a dose of 150 mg/kg administered perorally twice daily for a period of 8 days.1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID111010Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID210311Cytotoxic activity against human tumor TSGH 8302 cell line1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
AID103158Antitumor activity in vivo expressed as percent of inhibition in M-5-ovarian carcinoma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID43976Antitumor activity in vivo expressed as percent of inhibition in C3H-mammary adenocarcinoma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID115738Tumor growth inhibition determined at day 20 after tumor transplantation in mice at dose of 300 mg/kg oral administration1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
AID44016Concentration required to inhibit growth of CCRF-CEM cells in culture for 72 hr to 50% of control growth1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID187239Hypoglycemic activity expressed as (Maximum reduction in blood glucose in mg/dL relative to predosing glucose level)/(time in hours at which maximum reduction occurred); 63/31990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID42419Antitumor activity in vivo expressed as percent of inhibition in CA-755-mammary adenocarcinoma tumor cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID38320Antitumor activity in vivo expressed as percent of inhibition in B-16-melanoma cell myeloma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID7289Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID95823Cytotoxic activity against human tumor KB cell line1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
AID46286Cytotoxic activity against human tumor COLO 205 cell line1997Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14
Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's19 (95.00)18.2507
2000's1 (5.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.06 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
dimethyl sulfoxide
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.		1.9910sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
5-dimethylamiloride
5-dimethylamiloride: has anti-HIV-1 activity		1.9810
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		1.9810
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		2.3820aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
ethylmaleimide
Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.		1.9810maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		1.9710N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		1.9710adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
tolcyclamide
[no description available]		1.9710sulfonamide
amiloride
Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.		1.9810aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
dithiothreitol
1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.		1.99101,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
transferrin
Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.		1.9810
sodium azide
Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).		1.9710inorganic sodium saltantibacterial agent;
explosive;
mitochondrial respiratory-chain inhibitor;
mutagen
azides
Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.		1.9710pseudohalide anionmitochondrial respiratory-chain inhibitor
nigericin
Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.		1.9710polycyclic etherantibacterial agent;
antimicrobial agent;
bacterial metabolite;
potassium ionophore
diflubenzuron
Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group.		1.9710benzoylurea insecticide;
monochlorobenzenes		insect sterilant
sulofenur
sulofenur: a diarylsulfonylurea		2.8940
hexacyanoferrate iii
hexacyanoferrate III: RN given refers to parent cpd		1.9810
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.382011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		2.0110capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
valinomycin
Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.		1.9710cyclodepsipeptide;
macrocycle		antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore
rhodamine 123
Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.		1.9710organic cation;
xanthene dye		fluorochrome
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		2.6830organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
epidermal growth factor
Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.		1.9910
oligomycins
Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).		2.3820
2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Adenocarcinoma, Basal Cell
[description not available]		03.0750
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		01.9710
Kahler Disease
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		03.0750
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		01.9710
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		01.9710
EHS Tumor
[description not available]		01.9910
B16 Melanoma
[description not available]		01.9910
Cancer of Colon
[description not available]		02.6730
Colonic Neoplasms
Tumors or cancer of the COLON.		02.6730
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		01.9710
Benign Neoplasms
[description not available]		01.9910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		01.9910
Cancer of Prostate
[description not available]		01.9810
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9810